Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Cantor Fitzgerald
Dow
Moodys
Federal Trade Commission
Chinese Patent Office
Argus Health
Farmers Insurance

Generated: July 21, 2018

DrugPatentWatch Database Preview

Lenvatinib mesylate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for lenvatinib mesylate and what is the scope of lenvatinib mesylate freedom to operate?

Lenvatinib mesylate
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenvatinib mesylate has one hundred and seven patent family members in thirty countries.

There is one drug master file entry for lenvatinib mesylate. One supplier is listed for this compound.
Summary for lenvatinib mesylate
International Patents:107
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Suppliers / Packagers: 1
Bulk Api Vendors: 20
Clinical Trials: 2
Patent Applications: 15
DailyMed Link:lenvatinib mesylate at DailyMed
Pharmacology for lenvatinib mesylate
Synonyms for lenvatinib mesylate
3J78384F61
4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate
6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium methanesulfonate
6-Quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, methanesulfonate (1:1)
857890-39-2
AKOS030632716
CHEBI:85995
CHEMBL2105704
D09920
DTXSID90235081
HE071028
KB-145996
KS-00000TO1
Lenvatinib mesilate
Lenvatinib mesilate (JAN)
Lenvatinib mesylate (USAN)
Lenvatinib mesylate [USAN]
LENVATINIB; METHANESULFONIC ACID
Lenvima (TN)
methanesulfonic acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)
MFCD18633219
N-(4-((6-Carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-N'-cyclopropylurea monomethanesulfonate
SCHEMBL865174
UNII-3J78384F61

US Patents and Regulatory Information for lenvatinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for lenvatinib mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,092 Nitrogen-containing aromatic derivatives ➤ Sign Up
7,973,160 Nitrogen-containing aromatic derivatives ➤ Sign Up
8,372,981 Nitrogen-containing aromatic derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for lenvatinib mesylate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015039 Lithuania ➤ Sign Up PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
/2015 Austria ➤ Sign Up PRODUCT NAME: LENVATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/15/1002/001-002 (MITTEILUNG) 20150601
2015000083 Germany ➤ Sign Up PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
2015 00053 Denmark ➤ Sign Up PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT DERAF, HERUNDER LENVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Express Scripts
Baxter
Medtronic
Deloitte
Healthtrust
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.